Search Results

Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.

Freeline Therapeutics Holdings plc and Syncona Ltd announced that Freeline’s shareholders have approved the proposal for Bidco 1354 Limited, a wholly owned subsidiary of Syncona Portfolio Limited, to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share in cash.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has entered into a definitive agreement with a newly established portfolio company of Syncona Ltd.

Freeline Therapeutics Holdings plc and Syncona Ltd announced that, in connection with Syncona’s acquisition of Freeline by way of a scheme of arrangement, the Scheme has been sanctioned by the Court and the court order has been delivered to the Registrar of Companies.

Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update.

Freeline Therapeutics Holdings plc announced that the company will be participating in two upcoming investor conferences in August.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the second quarter of 2023 and provided a business update.

Freeline Therapeutics announced new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus gene therapy candidate for Gaucher disease, showing substantial reductions in glucosylsphinogsine, one of the best predictors of clinical response, in patients with persistently high levels despite years of treatment with currently approved therapies, as well as early signs of clinical improvements in bone marrow burden and fatigue.

Forcefield Therapeutics (“Forcefield”) Ltd, a pioneer of best-in-class therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction, and Freeline Therapeutics have entered into an exclusive patent and know-how license agreement.